Prosecution Insights
Last updated: October 02, 2026

Curevac Manufacturing GmbH

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Curevac Manufacturing GmbH has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners and 3 distinct art units. NGUYEN, QUANG is the busiest examiner, with 2 pending office actions currently assigned. The portfolio's 5 pending actions are spread across 3 distinct art units, indicating a variety of technical focuses within biotechnology.

With 4 distinct examiners involved, the company interacts with multiple officials, though NGUYEN, QUANG handles 2 of the 5 total actions. This distribution balances the workload while maintaining a presence in 3 distinct art units. The ratio of 5 actions to 4 examiners shows that most examiners handle a single case while the busiest examiner handles 2. The involvement of 3 distinct art units suggests that the company's technology is being evaluated by different technical sections of the patent office. NGUYEN, QUANG is the busiest examiner for these 5 pending office actions.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
4
Medium (80%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (60%)
Double-patenting + other1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NGUYEN, QUANG 2 38.0% +52.6%
BAKSHI, PANCHAM 1 76.8% +30.2%
DACE DENITO, ALEXANDRA GERALDINE 1 56.3% +40.2%
ADAMS, MICHELLE 1 58.6% +40.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18432898 METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION ADAMS, MICHELLE 42d overdue

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18432898 METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION ADAMS, MICHELLE 42d overdue
19363455 METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION BAKSHI, PANCHAM —
18582620 METHODS AND MEANS FOR ENHANCING RNA PRODUCTION DACE DENITO, ALEXANDRA GERALDINE —
17932026 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE NGUYEN, QUANG —
15750745 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE NGUYEN, QUANG —

Top Art Units

Art UnitApps
1631 2
1623 1
1797 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19363455 METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION BAKSHI, PANCHAM 1623 §103 Non-Final OA — Pending Oct 20, 2025
18582620 METHODS AND MEANS FOR ENHANCING RNA PRODUCTION DACE DENITO, ALEXANDRA GERALDINE — §103§112DP Non-Final OA — Pending Feb 20, 2024
18432898 METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION ADAMS, MICHELLE 1797 §103§112 Final Rejection 42d overdue Pending Feb 05, 2024
17932026 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE NGUYEN, QUANG 1631 §103 Final Rejection — Pending Sep 14, 2022
15750745 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE NGUYEN, QUANG 1631 §103 Final Rejection — Pending Feb 06, 2018

Managing Curevac Manufacturing GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month